PartnershipMay 14, 2026, 05:22 PM
CEL-SCI & Amarox Ink 50/50 Revenue Share Deal for Multikine
AI Summary
CEL-SCI Corporation announced a strategic partnership, distribution, and revenue sharing agreement with Amarox for its cancer immunotherapy, Multikine, in Saudi Arabia. The agreement includes a 50%/50% net revenue sharing model for sales of Multikine, intended for head and neck cancer treatment, upon SFDA approval. Amarox will manage local regulatory processes, including seeking Breakthrough Medicine Designation, and will be the exclusive distributor in Saudi Arabia, with an option to expand to other GCC countries. This collaboration aims to accelerate Multikine's commercialization in a region where the immunotherapy market is projected to reach $2.7 billion by 2033.
Key Highlights
- CEL-SCI signed a strategic partnership with Amarox for Multikine in Saudi Arabia.
- Agreement includes a 50%/50% net revenue sharing for Multikine sales.
- Amarox to lead regulatory affairs with SFDA, seeking Breakthrough Medicine Designation.
- Amarox will be the exclusive distributor in Saudi Arabia upon SFDA approval.
- Optional expansion of distribution rights to GCC countries.
- Saudi immunotherapy market projected to reach $2.7 billion by 2033.
- Amarox's financial obligation limited to 50% of SFDA product registration fees.
- Agreement term is 5 years from first commercial sale, with 1-year renewals.